0001209191-20-044663.txt : 20200804
0001209191-20-044663.hdr.sgml : 20200804
20200804160306
ACCESSION NUMBER: 0001209191-20-044663
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200731
FILED AS OF DATE: 20200804
DATE AS OF CHANGE: 20200804
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hearne Michael S
CENTRAL INDEX KEY: 0001759910
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38318
FILM NUMBER: 201073275
MAIL ADDRESS:
STREET 1: 4147 EXECUTIVE DRIVE
STREET 2: SUITE 510
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Odonate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001717452
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822493065
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE
STREET 2: SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-200-3830
MAIL ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE
STREET 2: SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Odonate Therapeutics, Inc
DATE OF NAME CHANGE: 20171207
FORMER COMPANY:
FORMER CONFORMED NAME: Odonate Therapeutics, LLC
DATE OF NAME CHANGE: 20170919
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-31
0
0001717452
Odonate Therapeutics, Inc.
ODT
0001759910
Hearne Michael S
C/O ODONATE THERAPEUTICS, INC.
4747 EXECUTIVE DRIVE, SUITE 210
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
Common Stock
2020-07-31
4
A
0
18
30.91
A
1730
D
Common Stock
14075269
I
By LP
Employee Stock Option (Right to Buy)
36.37
2020-07-31
4
A
0
18
0.00
A
2030-07-31
Common Stock
18
18
D
These shares were acquired on 07/31/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in a portion of the shares beneficially held by TCP.
The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.
/s/ Michael Hearne
2020-08-04